factual
FDA Amplified Rare Edge Cases to Yank Vaccine
The FDA is not optimized for correct tradeoffs between type-one and type-two errors, as shown when it amplified very rare thrombosis edge cases to yank the Johnson & Johnson vaccine despite large-scale benefit, and when in February 2020 it made it very hard to run diagnostics on the novel coronavirus until the Seattle Flu Study committed civil disobedience.
factualpending
Speaker
Balaji SrinivasanEvidence Quote
“they're not optimized for making the correct trade-off between type one and type two errors”
Created: 6/14/2026, 2:23:35 AM
Your notes
Loading notes...